Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Leung, D. Y. [1 ]
Cork, M. J. [2 ]
Ong, P. [3 ]
Danby, S. [2 ]
Ramirez-Gama, M. [1 ]
Garcia, S. [1 ]
Taylor, P. [1 ]
Zahn, J. [4 ]
Bologna, G. [5 ]
Zhang, A. [5 ]
机构：
[1] Natl Jewish Hlth, Denver, CO USA
[2] Univ Sheffield, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
[3] Univ Southern Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[5] Sanofi, Cambridge, MA USA
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000487
引用
收藏
页码：194 / 194
页数：1
相关论文
共 50 条
  • [1] Dupilumab treatment normalizes skin barrier function in children aged 6-11 years with moderate-to-severe atopic dermatitis
    Cork, Michael J.
    Leung, Donald
    Ong, Peck
    Danby, Simon
    Ramirez-Gama, Marco
    Garcia, Shannon
    Patricia, Taylor
    Byers, Rob
    Matcher, Stephen
    Zahn, Joseph
    Bologna, Gabriel
    Zhang, Annie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I30 - I30
  • [2] Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Leung, D. Y. M.
    Ong, P.
    Danby, S. G.
    Ramirez-Gama, M.
    Garcia, S.
    Taylor, P.
    Zahn, J.
    Praestgaard, A.
    Bologna, G.
    Zhang, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S342 - S342
  • [3] Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (02) : E39 - E39
  • [4] Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6-11 years with and without comorbid asthma
    Prescilla, R.
    Bieber, T.
    Boguniewicz, M.
    Siegfried, E. C.
    Chen, Z.
    Shumel, B.
    ALLERGY, 2021, 76 : 229 - 229
  • [5] Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6-11 Years With And Without Comorbid Asthma
    Boguniewicz, Mark
    Sher, Lawrence
    Paller, Amy
    Siegfried, Elaine
    Chen, Zhen
    Prescilla, Randy
    Shumel, Brad
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB32 - AB32
  • [6] Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6-11 years with and without comorbid allergic rhinitis
    Prescilla, R.
    Wollenberg, A.
    Siegfried, E. C.
    Chen, Z.
    Abramova, A.
    ALLERGY, 2021, 76 : 229 - 229
  • [7] EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Worrell, Richard
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Dubost-Brama, Ariane
    Bansal, Ashish
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 31 - 32
  • [8] Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis
    Berdyshev, Evgeny
    Goleva, Elena
    Bissonnette, Robert
    Bronova, Irina
    Bronoff, Anna Sofia
    Richers, Brittany N.
    Garcia, Shannon
    Ramirez-Gama, Marco
    Taylor, Patricia
    Praestgaard, Amy
    Agueusop, Inoncent
    Jurvilliers, Pauline
    Boguniewicz, Mark
    Levit, Noah A.
    Rossi, Ana B.
    Zhang, Annie
    Leung, Donald Y. M.
    ALLERGY, 2022, 77 (11) : 3388 - 3397
  • [9] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
    Paller, A. S.
    Siegfried, E. C.
    Yosipovitch, G.
    Kwatra, S. G.
    Praestgaard, A.
    Prescilla, R.
    Wang, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
  • [10] Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6-11 Years With And Without Comorbid Allergic Rhinitis
    Beck, Lisa
    Wollenberg, Andreas
    Paller, Amy
    Siegfried, Elaine
    Chen, Zhen
    Abramova, Alvina
    Prescilla, Randy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB144 - AB144
12345